Citations

Clear

127 citation(s) found for "McCormick, A".

Intrinsic properties of spinal motoneurons degrade ankle torque control in humans
Beauchamp, James A. , Khurram, Obaid U. , Negro, Francesco , Dewald, Julius P. A. , Pearcey, Gregory E P , Khurram, Obaid U , Negro, Francesco , Dewald, Julius P A , Heckman, C J

Mayo Clinic

The Journal of Physiology | March 30, 2025 | Volume: 603 | Issue: 8 | Pages: 2443-2463

10.1113/jp287446 | PMID 40153847 Get It

Abstract Motoneurons are the final common pathway for all motor commands and possess intrinsic electrical properties that must be tuned to control muscle across the full range of motor behaviours. Neuromodulatory input from the brainstem is probably essential for adapting motoneuron properties to match this diversity of motor tasks. A primary mechanism of this adaptation, control of dendritic persistent inward currents (PICs) in motoneurons by brainstem monoaminergic systems, generates both amplification and prolongation of synaptic inputs. While essential, there is an inherent tension between this amplification and prolongation. Although amplification by PICs allows for quick recruitment and acceleration of motoneuron discharge, PICs must be deactivated to derecruit motoneurons upon movement cessation. In contrast, during stabilizing or postural tasks, PIC‐induced prolongation of synaptic inputs is critical for sustained motoneuron discharge. Here, we designed two motor tasks that challenged the inhibitory control of PICs, generating unduly PIC prolongation that increases variability in human torque control. This included a paradigm combining a discrete motor task with a stabilizing task and another involving muscle length‐induced changes to the balance of excitatory and inhibitory inputs available for controlling PICs. We show that prolongation from PICs introduces difficulties in ankle torque control and that these difficulties are further degraded at shorter muscle lengths when PIC prolongation is greatest. These results highlight the necessity for inhibitory control of PICs and showcase issues introduced when inhibitory control is constrained. Our findings suggest that, like sensory systems, errors are inherent in motor systems. These errors are not due to problems in the perception of movement‐related sensory input but are embedded in the final stage of motor output. This has many implications relevant to clinical conditions (e.g. chronic stroke) where pathological shifts in monoamines may further amplify these errors. image Key points All motor commands are processed via spinal motoneurons, whose intrinsic electrical properties are adapted by brainstem neuromodulatory input. The effects of these neuromodulatory inputs (i.e. persistent inward currents; PICs) must be tightly regulated by inhibitory inputs to allow for the large repertoire of human motor behaviours. We designed two motor tasks to restrict the ability of inhibitory synaptic inputs to control PICs and show that this generates substantial errors that reduce the precision of motor output in humans. Our findings suggest that errors are inherent in motor systems and embedded in the final stage of motor output. This has many implications relevant to clinical conditions (e.g. chronic stroke) and may, speculatively, shed light on contributing factors to muscle cramps.
Genomic Screening at a Single Health System
Savatt, Juliann M. , Sturm, Amy C. , McCormick, Cara Z., Nixon, Michelle Pistner , Rolston, David D.K. , Wain, Karen E. , Willard, Huntington F. , Faucett, W. Andrew , Ledbetter, David H., Buchanan, Adam H. , Martin, Christa L., Strande, Natasha T. , Sturm, Amy C , Kelly, Melissa , Williams, Marc S , Martin, Christa L.

Mayo Clinic

JAMA Network Open | March 17, 2025 | Volume: 8 | Issue: 3 | Pages: e250917

10.1001/jamanetworkopen.2025.0917 | PMID 40094662 Get It

Importance Completion of the Human Genome Project prompted predictions that genomics would transform medicine, including through genomic screening that identifies potentially medically actionable findings that could prevent disease, detect it earlier, or treat it better. However, genomic screening remains anchored in research and largely unavailable as part of routine care. Objective To summarize 11 years of experience with genomic screening and explore the landscape of genomic screening efforts. Design, Setting, and Participants This cohort study was based in Geisinger’s MyCode Community Health Initiative, a genomic screening program in a rural Pennsylvania health care system in which patient-participants exomes are analyzed. Main Outcomes and Measures Genomic screen-positive rates were evaluated and stratified by condition type (cancer, cardiovascular, other) and US Centers for Disease Control and Prevention (CDC) Tier 1 designation. The proportion of participants previously unaware of their genomic result was assessed. Other large-scale population-based genomic screening efforts with genomic results disclosure were compiled from public resources. Results A total of 354 957 patients participated in Geisinger’s genomic screening program (median [IQR] age, 54 [36-69] years; 194 037 [59.7%] assigned female sex at birth). As of June 2024, 175 500 participants had exome sequencing available for analysis, and 5934 participants (3.4%) had a pathogenic variant in 81 genes known to increase risk for disease. Between 2013 and July 2024, 5119 results were disclosed to 5052 eligible participants, with 2267 (44.2%) associated with risk for cardiovascular disease, 2031 (39.7%) with risk for cancer, and 821 (16.0%) with risk for other conditions. Most results (3040 [59.4%]) were in genes outside of those with a CDC Tier 1 designation. Nearly 90% of participants (4425 [87.6%]) were unaware of their genomic risk prior to disclosure. In a survey of large-scale biobanks with genomic and electronic health record (EHR) data, only 25.0% (6 of 24) disclosed potentially actionable genomic results. Conclusions and Relevance In this large, genomics-informed cohort study from a single health system, 1 in 30 participants had a potentially actionable genomic finding. However, nearly 90% were unaware of their risk prior to screening, demonstrating the utility of genomic screening in identifying at-risk individuals. Most large-scale biobanks with genomic and EHR data did not return genomic results with potential medical relevance, missing opportunities to significantly improve genomic risk ascertainment for these individuals and to perform longitudinal studies of clinical and implementation outcomes in diverse settings.
Strengthening Discovery and Application of Artificial Intelligence in Anesthesiology: A Report from the Anesthesia Research Council
Lonsdale, Hannah , Burns, Michael , Epstein, Richard H. , Hofer, Ira , Tighe, Patrick , Delgado, J. Arias , Kor, Daryl J. , MacKay, Emily J. , Rashidi, Parisa , Wanderer, Jonathan P. , Hofer, Ira S , Tighe, Patrick J , Gálvez Delgado, Julia A , McCormick, Patrick J

Mayo Clinic

Anesthesia & Analgesia | March 14, 2025 | Volume: 140 | Issue: 4 | Pages: 920-930

10.1213/ane.0000000000007474 | PMID 40305700 Get It

Interest in the potential applications of artificial intelligence in medicine, anesthesiology, and the world at large has never been higher. The Anesthesia Research Council steering committee formed an anesthesiologist artificial intelligence expert workgroup charged with evaluating the current state of artificial intelligence in anesthesiology, providing examples of future artificial intelligence applications and identifying barriers to artificial intelligence progress. The workgroup’s findings are summarized here, starting with a brief introduction to artificial intelligence for clinicians, followed by overviews of current and anticipated artificial intelligence–focused research and applications in anesthesiology. Anesthesiology’s progress in artificial intelligence is compared to that of other medical specialties, and barriers to artificial intelligence development and implementation in our specialty are discussed. The workgroup’s recommendations address stakeholders in policymaking, research, development, implementation, training, and use of artificial intelligence–based tools for perioperative care.
Strengthening Discovery and Application of Artificial Intelligence in Anesthesiology: A Report from the Anesthesia Research Council
Lonsdale, Hannah , Burns, Michael , Epstein, Richard H. , Hofer, Ira , Tighe, Patrick , Delgado, J. Arias , Kor, Daryl J. , MacKay, Emily J. , Rashidi, Parisa , Wanderer, Jonathan P. , Hofer, Ira S , Tighe, Patrick J , Gálvez Delgado, Julia A , McCormick, Patrick J

Mayo Clinic

Anesthesiology | March 11, 2025 | Volume: 142 | Issue: 4 | Pages: 599-610

10.1097/aln.0000000000005326 | PMID 40067037 Get It

Interest in the potential applications of artificial intelligence in medicine, anesthesiology, and the world at large has never been higher. The Anesthesia Research Council steering committee formed an anesthesiologist artificial intelligence expert workgroup charged with evaluating the current state of artificial intelligence in anesthesiology, providing examples of future artificial intelligence applications and identifying barriers to artificial intelligence progress. The workgroup’s findings are summarized here, starting with a brief introduction to artificial intelligence for clinicians, followed by overviews of current and anticipated artificial intelligence–focused research and applications in anesthesiology. Anesthesiology’s progress in artificial intelligence is compared to that of other medical specialties, and barriers to artificial intelligence development and implementation in our specialty are discussed. The workgroup’s recommendations address stakeholders in policymaking, research, development, implementation, training, and use of artificial intelligence–based tools for perioperative care.
Real‐World Outcomes of Relapsed/Refractory Core‐Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study
Rojek, Alexandra E. , McCormick, Benjamin J. , Odetola, Oluwatobi , Abaza, Yasmin , Nai, Nhi , Foucar, Charles , Achar, Rohan K. , Shallis, Rory M. , Bradshaw, Danielle , Standridge, Meaghan, Badar, Talha , Patel, Anand , Abaza, Yasmin , Nai, Nhi , Kota, Vamsi , Badar, Talha , Patel, Anand , Rojek, Alexandra E , Cwykiel, Joanna M. , Kota, Vamsi , Murthy, Guru Subramanian Guru

Mayo Clinic

American Journal of Hematology | March 10, 2025 | Volume: 100 | Issue: 6 | Pages: 1082-1085

10.1002/ajh.27664 | PMID 40062542 Get It

Recognition of the Large Ambulatory C2D Stage of Advanced Heart Failure—A Call to Action
Lala, Anuradha , Stewart, Garrick C. , Wong, Renee , Morris, Alanna A. , Breathett, Khadijah , Cogswell, Rebecca , Colvin, Monica , Drakos, Stavros , Gelfman, Laura P. , Kanwar, Manreet , Kittleson, M. , Lewis, Eldrin F. , Ogunniyi, Modele O. , Pandey, Ambarish , Rogers, Joseph G. , Teuteberg, Jeffrey J. , Valantine, Hannah A. , Dixon, Debra , Hanff, Thomas C. , Hsiao, Stephanie, McCormick, Amanda D. , Fenton, Kathleen N. , Longacre, Lisa Schwartz, Shanbhag, Sujata M., Taddei‐Peters, Wendy C. , Stevenson, L W, Dunlay, Shannon M. , Kanwar, Manreet K , Breathett, Khadijah , McCormick, A , Colvin, Monica M , Pinney, Sean P , McIlvennan, Colleen Kelley , Pagani, Francis D. , Allen, Larry A. , Cowger, Jennifer , Kiernan, Michael S. , Moazami, Nader , Pandey, Ambarish , Schumacher, Kurt R. , Slaughter, Mark S. , Tedford, Ryan J. , DeFilippis, Ersilia M. , Golbus, Jessica R , Gulati, Gaurav , Lewsey, Sabra C , Nayak, Aditi , Stevenson, Lynne W.

Mayo Clinic

JAMA Cardiology | February 5, 2025 | Volume: 10 | Issue: 4 | Pages: 391

10.1001/jamacardio.2024.5328 | PMID 39908057 Get It

ImportanceThe advanced ambulatory heart failure (HF) population comprises patients who have progressed beyond the pillars of recommended stage C HF therapies but can still find meaningful life-years ahead. Although these patients are commonly encountered in practice, national databases selectively capture the small groups accepted for heart transplant listing or left ventricular assist devices. The epidemiology, trajectories, and therapies for other ambulatory patients with advanced HF are poorly understood.ObservationsIn December 2022, the National Heart, Lung and Blood Institute convened a team of experts to identify knowledge gaps and research priorities for the ambulatory population with limiting daily symptoms and transition toward refractory end-stage D HF, designated as stage C2D. This article summarizes the findings from that 3-day workshop. Workshop participants surveyed the initial challenges and knowledge gaps for (1) recognition of ambulatory C2D HF, (2) estimation of the magnitude of the affected population and identifiable subpopulations, and (3) physiologic phenotypes, such as low cardiac output, right HF, cardiorenal syndromes, congestive hepatopathy and frailty, which offer distinct targets for existing and emerging therapies. Social drivers of HF and patient preferences for quality/length of survival were highlighted as essential modifiers for personalization of therapies.Conclusions and RelevanceTen key points summarized workshop findings, with target cohorts for study proposed as a crucial next step. This workshop summary is intended as a call for action to address knowledge gaps and develop new strategies to improve outcomes in the large ambulatory population with C2D HF.
Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgery
Ganz, Patricia A. , Cecchini, Reena S. , White, Julia , Vicini, Frank A. , Arthur, Douglas W., Rabinovitch, Rachel , Kuske, Robert R. , Julian, Thomas B. , Parda, David S., Scheier, Michael F. , Winter, Kathryn, Paik, Soonmyung , Kuerer, Henry M. , Vallow, Laura A., Pierce, Lori J. , Mamounas, Eleftherios P. , Germain, Isabelle, Gustafson, Gregory S, Grossheim, Linda , Petersen, Ivy A. , Curran, Walter J. , White, Julia R , Hudes, Richard S , Wolmark, Norman , Mamounas, Eleftherios P. , McCormick, Beryl L. , Bear, Harry D. , Wolmark, Norman

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 10, 2024 | Volume: 117 | Issue: 1 | Pages: 103-111

10.1093/jnci/djae219 | PMID 39254630 Get It

Abstract Background NRG Oncology NSABP B-39/RTOG 0413 compared whole-breast irradiation (WBI) to accelerated partial-breast irradiation (APBI). APBI was not equivalent to WBI in local tumor control. Secondary outcome was quality of life (QOL). Methods The QOL sub-study used validated self-report questionnaires, including the Breast Cancer Treatment Outcome Scale (BCTOS) and the 36-Item Short Form Health Survey (SF-36) vitality scale. Assessments occurred before random assignment, at treatment completion (chemotherapy or radiotherapy), 4 weeks later, at 6, 12, 24, and 36 months. Primary aims: cosmesis change equivalency (baseline to 3 years; a priori margin of equivalence 0.4 standard deviations) and fatigue change superiority (baseline to end of treatment [EOT]) for APBI vs WBI, by patient groups treated with or without chemotherapy when appropriate. Results From March 21, 2005 to May 25, 2009, 975 patients enrolled in this sub-study; 950 had follow-up data. APBI had 3-year cosmesis equivalent to WBI (95% CI = -0.0001 to -0.16; equivalence margin -0.22 to -0.22) in all patients. The APBI group without chemotherapy had less EOT fatigue (P = .011; mean score APBI 63 vs WBI 59); the APBI group receiving chemotherapy had worse EOT fatigue (P = .011; APBI 43 vs WBI 49). The APBI group reported less pain (BCTOS) at EOT (WBI 2.29 vs APBI 1.97) but worse pain at 3 years (WBI 1.62 vs APBI 1.71). APBI patients reported greater convenience of care than with WBI and reported less symptom severity at EOT and 4 weeks later. Conclusion Cosmetic outcomes were similar for the APBI and WBI groups, with small statistically significant differences in other outcomes that varied over time. Differences in fatigue and other symptoms appeared to resolve by ≥6 months. APBI may be preferred by some patients, for whom extended treatment is burdensome. ClinicalTrials.gov NCT00103181.
Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia
Rojek, Alexandra E. , McCormick, Benjamin J. , Odetola, Oluwatobi , Nai, Nhi , Foucar, Charles , Achar, Rohan K. , Shallis, Rory M. , Bradshaw, Danielle , Standridge, Meaghan, Badar, Talha , Patel, Anand , Foucar, Charles E , Patel, Anand , Badar, Talha , Rojek, Alexandra E , Cwykiel, Joanna M. , Abaza, Yasmin , Kota, Vamsi , Murthy, Guru Subramanian Guru

Mayo Clinic

eJHaem | July 24, 2024 | Volume: 5 | Issue: 4 | Pages: 728-737

10.1002/jha2.981 | PMID 39157611 Get It

AbstractCore‐binding factor acute myeloid leukemia (CBF‐AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and is classified as a favorable risk by the 2022 European LeukemiaNet (ELN) guidelines. The CD33‐targeting antibody‐drug conjugate, gemtuzumab ozogamicin (GO), is commonly added to intensive chemotherapy (IC) in CBF‐AML. We sought to compare outcomes in patients treated with IC with or without GO in CBF‐AML. We included 200 patients with CBF‐AML treated with IC across seven academic centers. Induction treatment regimens were categorized as IC alone, IC with GO, or IC with KIT inhibitor (dasatinib or midostaurin). Median follow‐up for the whole cohort was 2.5 years. Three‐year overall survival (OS) was 70% and 3‐year event‐free survival (EFS) was 51%. Patients treated with IC with GO experienced a 3‐year EFS of 50% compared to those treated with IC alone who experienced a 3‐year EFS of 47%, with no statistically significant difference (p = 0.62). Similarly, those treated with IC with GO did not experience an improved OS compared to those treated with IC alone (p = 0.67). Patients treated with IC with KIT inhibitor experienced a significantly improved 3‐year EFS of 85% compared to those with IC with or without GO (p = 0.04). We find in our study that there is no survival benefit in patients treated with IC with the addition of GO; improved EFS was seen in patients with CBF‐AML treated with IC plus KIT inhibitors, consistent with outcomes noted in prospective studies utilizing this approach.
Changes in nutritional status and the development of obesity and metabolic syndrome following pediatric heart transplantation
Sill, Jordan , Lukich, S., Alejos, A., Lim, H. , Chau, P., Lowery, Ray , McCormick, Amanda D. , Peng, David M. , Yu, Stella X. , Schumacher, Kurt R. , Lim, Heang M. , Sill, J , McCormick, A , Peng, D M , Schumacher, K R , Yu, S., Lim, Heang M.

Mayo Clinic

Pediatric Transplantation | May 20, 2024 | Volume: 28 | Issue: 4 | Pages: No page available

10.1111/petr.14782 | PMID 38767001 Get It

AbstractBackgroundNutritional status in pediatric patients undergoing heart transplantation (HT) is frequently a focus of clinical management and requires high resource utilization. Pre‐operative nutrition status has been shown to affect post‐operative mortality but no studies have been performed to assess how nutritional status may change and the risk of developing nutritional comorbidities long‐term in the post‐transplant period.MethodsA single‐center retrospective chart review of patients ≥2 years of age who underwent heart transplantation between 1/1/2005 and 4/30/2020 was performed. Patient data were collected at listing, time of transplant, 1‐year, and 3‐year follow‐up post‐transplant. Nutrition status was classified based on body mass index (BMI) percentile in the primary analysis. Alternative nutritional indices, namely the nutrition risk index (NRI), prognostic nutrition index (PNI), and BMI z‐score, were utilized in secondary analyses.ResultsOf the 63 patients included, the proportion of patients with overweight/obese status increased from 21% at listing to 41% at 3‐year follow‐up. No underweight patients at listing became overweight/obese at follow‐up. Of patients who were overweight/obese at listing, 88% maintained that status at 3‐year follow‐up. Overweight/obese status at listing, 1‐year, and 3‐year post‐transplantation were significantly associated with developing metabolic syndrome. In comparison to the alternative nutritional indices, BMI percentile best predicted post‐transplant metabolic syndrome.ConclusionsThe results suggest that pediatric patients who undergo heart transplantation are at risk of developing overweight/obesity and related nutritional sequelae (ie, metabolic syndrome). Improved surveillance and interventions targeted toward overweight/obese HT patients should be investigated to reduce the burden of associated comorbidities.
Clinical Features of Cutaneous Paraneoplastic Syndromes in Hodgkin Lymphoma
McCormick, Benjamin J. , Zieman, Daniel, Sluzevich, Jason C. , Moustafa, Muhamad Alhaj , Moustafa, Muhamad Alhaj , Sluzevich, Jason C

Mayo Clinic

Journal of Investigative Medicine High Impact Case Reports | May 20, 2024 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/23247096241255840 | PMID 38767173 Get It

Cutaneous paraneoplastic syndromes due to Hodgkin lymphoma present with a wide spectrum of clinical manifestations from generalized pruritus to exfoliative erythroderma. We summarize the clinical findings and outcomes of 14 patients with Hodgkin lymphoma and associated cutaneous paraneoplastic syndromes treated at Mayo Clinic over the past 3 decades. Cutaneous paraneoplastic syndromes may be present at the time of lymphoma diagnosis, whereas in other patients, it may appear at the time of relapse, including patients with initial absence of cutaneous manifestations during the initial lymphoma presentation. Our results indicate that complete resolution of the paraneoplastic syndrome is associated with significantly improved overall survival. Recognition of cutaneous paraneoplastic syndromes is a crucial surrogate of relapsed malignancy and treatment requires targeting the underlying malignancy.